A couple of minor modifications were made in the method implementation: (i) the number of random signatures to be tested was increased from 1000 to 2000 and (ii) a gene to be selected to the initial signature had to be included in 2 (rather than 3) random signatures that met the criteria of AUC (> 0.65) and p-value (< 0.0001) in predicting the BCR statuses of the TCGA-PRAD samples. Here, BCR is linked to prostate adenocarcinoma.